The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Can anyone shed any light on the large trades reported today?
Thanks for that summary of your point of view Toyin, understandable and logical. Totally agree with your final statement. Fingers crossed.
PGlancy, your theory is valid and the market seems to agree with you, hence 10p share price. I would have thought that between them they would be willing to hoover it up as everybody knows it is the biggest drag on the share price and considering what they already hold and what the new boys Unicorn stumped up, it's not a big ask. The only thing I can think of is that it won’t be eligible for EIS/VCT relief, that might be a stumbling block. This is why I want the Modi forecast asap as it would give plenty of liquidity to get rid of the CB. I think that is the closest low hanging fruit regarding actual price changing news, subject to it being a strong forecast which I believe it should be based on the figures opti have published (I know that’s a bit lame but its all we have to go on). This is my biggest frustration at the moment, Morepen aren’t launching until July, yet SOH has a detailed five year forecast, Modi launched nearly three months ago and we have nothing.
The M&A and Axis, I agree its been disappointing but I would guess the CB was going to be used for acquisition two, after the backlash he will have needed to sort alternative funding, maybe that’s the delay. On Croda, I lay the blame with Croda, management had anticipated revenues in 22 & 23 which didn’t materialised, the nomad and board must have had information from Croda to allow this to be put in the rns'. Then in the presentation they pat themselves on the back for getting it done in less than five years when it normally takes seven, but initially signed a four year deal, this I cannot fathom.
It is very frustrating but lets hope that Modi/Croda pull us out the hole very soon.
Could it be the patent belongs to uom and nothing to do with Sbtx. I have a contract within the NHS which stipulates anything I developed under the terms of contract belongs to it and I cannot approach a 3rd part with a view of commercilising it.
Toyin what do you think about my theory SA is struggling to clear the cln with new or existing stakeholders because he cannot get a forecast from croda or modi and without these the may be a concern anything from SA himself will not be trusted due to his inflated launch of axis which is very poor even today. In some ways we are better off with 3rd party forecasts because they are likely to be trusted given SA history of over promising and under delivering in terms of revenues and timing. The latter is a concern because he keeps repeating school boy errors. The expected delivery of 2nd m&a and news on axis and croda results have come and gone without a whiff.
Catherine O'Neill
Applied Feb 22
Published Apr 24
https://patents.justia.com/patent/20240131089#history
not assigned as yet to skin apparently
others
https://patents.justia.com/inventor/catherine-o-neill
mol
Let's keep it pleasant folks, we are all in the same boat. I understand the frustration but let's look forward to the near term upside. CB being cleared, Modi forecast & Croda forecast. Modi launched 1st March so they must be close and Croda is forward selling the lysate when the external trial finishes in week 1 June. Either one of those forecasts could put us multiples of where we are now and they are just around the corner.
No need to get abusive Mad, you lose all credibility when you tell porkies like you did about me yesterday.
As for Ashman he never sticks to what he says.
Give it a rest Bazzaman you’re like a broken record. Why don’t you email Ashman and ask him your questions? He’s always answered mine and many others. Troll somewhere else nutter.
Check out SBTX website, presentation on page 1 is from October 2021. About time they updated it really, sums up how the company views its whole package.
Always difficult to compare like for like companies but other health companies I'm invested in present on results, contract wins etc. In Skins case I would expect Ashman to update monthly as a minimum & stop moving the goalposts. There us plenty of information he could share with us but clearly chooses not to, hiding behind some Nomads complaint about Elric's paywall. All pathetic really.
Note the US FDA definition of a Skincare Active and that currently there are no Anti-aging ingredients that meet the FDA's criteria, perhaps the Croda Clinical Trials will change that?
Also, prevention of sunburn falls under the "Drug/Medicinal" category rather than Cosmetic so presume under the terms of the current Croda agreement we can sell the lysate for incorporation into say a sunscreen but Croda cannot if found to have SPF properties?
https://www.rodanandfields.com/en-us/blog/science-of-skincare/what-is-an-active-ingredient-in-skincare/
And how many presentations do most listed companies carry out then Bazza, one or two a year with the Interims and FY results I suggest
6 presentations a year out of around 240 work days, sums up his commitment really - pathetic.
We have a CEO who is an idiot and Croda may be marketing a cosmetic-changing product. Why is the market cap so low, Ashman's naivety and arrogance?
Looks like the SP creeping up has hit the buffers whilst Ashman contemplates his naval with his once every two months update. Does that mean the Acne results have had their goalposts moved from end of May till the end of June - who knows, ridiculous.
Mad, SA does intend to present towards the end of Jun; see his comment on a recent response to a couple of questions I raised and he kindly answered
Stuart,
First of all thankyou for the very full and positive presentation on the Investor Meets platform.
I have a couple of questions regarding the demarcation between the 5 Pillars, for instance we were informed by Greg that the Dermatonics Once Heel Balm is prescribed as a treatment by over 4500 GPs and Specialists so why is it only categorised in the Medical pillar rather than the Pharma Pillar as well and where would it sit if you were to separately list the Companies and why?
The boundaries between the Skinbiotix (Cosmetic) and Medical pillars are equally blurred. Whilst I appreciate that as an ingredient because of its many properties it can straddle all the pillars depending on its use, when it is used as a cosmetic to reduce wrinkles surely with the clinical evidence behind it, it is only the concentration of this active ingredient in a Customers final product that will determine whether it is medical (recommended by a specialist) or cosmetic? Assuming my assumption to be true, then as the current agreement with Croda is for cosmetic use only, and in some instances they supply the ingredient only and have no control over the concentration and which "premium products" their Customers use it in, wont you need to extend the terms of the agreement to include medical use?
Thanks in anticipation of a response
Firstly, please accept my apologies for the delayed response, your original message appears to have been filtered for some reason or other, this occasionally happens with mail from Hotmail addresses.
In answer to your questions please see below:
1. At this moment in time the Dermatonics once heel balm sits within the medical device pillar but does potentially hold a place within the pharmaceutical pillar. Products like this are often difficult to pigeonhole. The pillar approach was launched four years ago and, as with all strategies, we must remain somewhat flexible. In some countries the product is sold over the counter and this is where the blurring occurs. Were we to list the pillars individually we would need to have some form of end point carve out. We are monitoring endpoint purchase at present and will adjust accordingly.
2. This one is rather tricky, you are correct in your assumption that the lysate can be used in both cosmetic and medical applications. The Croda agreement relates very specifically to one sector of application, active skincare in the cosmetic field. Our agreement allows access to the finished product to then sell into the medical device space. This does not require an amendment to the agreement with Croda.
I will be updating the market as to recent progress before the end of June as per my commitment to deliver six presentations each year. We have conducted two IMC meetings thus far this year and are due another before end of Q2.
Many t
Fingers crossed Toyin. It would be great to see the CLNs gone by the time Croda launches so there is nothing to hold us back and no uncertainty about which easy the fortunes of the company are moving in.
Its £890,000 Mad, but looking at the trades and share action over the last few weeks I believe the CB is being worked through. Fingers crossed we are nearly done and can keep moving up.
You must be mixing me up with somebody else MAD, I've only posted once today and that was here.
Weird comment.
Well said Aquae, Bazzaman seems bored, he’s posted on several companies boards this morning, never anything particularly positive at any time. I prefer the slow rise to the big jumps, it keeps the market makers away. As I said earlier, as long as SA presents before the end of June he will have fulfilled his promise. Let’s hope the next announcement is a further reduction or clearance of the loan note. I’ve lost track of how much is remaining? Is it £800,000?
And yet the sp continues to creep up, perhaps silence is golden until there is something meaningful to report
Another day and radio silence from Ashman as he continues to treat shareholders with utter contempt.
mad, i understand what you are saying and whilst the news from croda and dermatonics was good, it wasn’t exactly going to give the share price a long lived lift, we need revenues for that. the cb is what it is but the way macquarie/clg have dumped was obviously not part of the plan. for me, i would prefer a very strong modi forecast that can clear the bond, get rid of the bankers and keep dilution to a minimum, i dont want to give these ****ers one more share than absolutely necessary. who knows where we are up to with the remainder, hopefully sa has got it away to long term shareholders like the first lot, i just want it/them gone asap.
Toyin, I'm merely pointing out a broad assumption based on the interims. A solid presentation with excellent news from Croda and Dermatonics and the SP shot up and then slipped back to previous lows. If he released acne or indeed anything else we are likely to see a brief rise and a return to previous pricing because of the looming spectre of the note. Why not clear the note and then release? I totally understand your approach and you are correct, I am just thinking of the unjust kicking he received from TW and the fact that many are baying for blood here and simply stating that of I were he then I would try to clear the note in its entirety and then issue news (that is assuming he is able to do that given the rules) Just my humble opinion.